SCHEMBL3654233

SCHEMBL3654233

COC(=O)c1ccc(-c2ccc(OC3CN(Cc4ccc(C(C)C)cc4)C3)cn2)cc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MLNR O43193 1/20 0.42
S1PR1 P21453 2/20 0.42
KCNH2 Q12809 1/20 0.41
MCHR1 Q99705 1/20 0.41
CHKA P35790 1/20 0.41
TP53 P04637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CNR1 P21554 1/20 0.40
PARP1 P09874 1/20 0.40
LMNA P02545 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
GCG P01275 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3660145 0.87 GCG (0.47) MEN1KMT2ASMN1; SMN2MLNRS1PR1
SCHEMBL6523552 0.80 GRM2 (0.40) MEN1KMT2AMLNRS1PR1KCNH2
SCHEMBL3659308 0.80 GPR119 (0.40) MEN1KMT2AMLNRS1PR1KCNH2
SCHEMBL3659215 0.79 MEN1 (0.53) MEN1KMT2AMAPTSMN1; SMN2S1PR1
SCHEMBL3660641 0.78 MEN1 (0.57) MEN1KMT2AS1PR1KCNH2MCHR1
SCHEMBL3809270 0.78 MCHR1 (0.42) MEN1KMT2AMLNRMCHR1PARP1
SCHEMBL6522775 0.77 MEN1 (0.56) MEN1KMT2AS1PR1KCNH2MCHR1
SCHEMBL6523290 0.76 MEN1 (0.52) MEN1KMT2ASMN1; SMN2KCNH2MCHR1
SCHEMBL3661425 0.76 MEN1 (0.43) MEN1KMT2AS1PR1PARP1HRH3
SCHEMBL13894795 0.76 MEN1 (0.43) MEN1KMT2AS1PR1KCNH2MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2011-03-10 US disclosed
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2011-03-10 US disclosed
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2011-03-10 US disclosed
EP-2215077-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS Prosidion Limited (GB) 2010-08-11 EP disclosed
WO-2009050522-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 WO disclosed
WO-2009050522-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists GPR119, GIPR, GPR39 MEN1 2395/4885KMT2A 3734/4885MAPT 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.